Rock Springs Capital Management LP Bei Gene, Ltd. Transaction History

Rock Springs Capital Management LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$249.6 - $403.14 $49.9 Million - $80.6 Million	-200,000 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$260.64 - $382.12 $6.52 Million - $9.55 Million	-25,000 Reduced 11.11%	200,000 $69.6 Million
Q4 2020 Feb 16, 2021	BUY	$221.31 - $316.61 $2.21 Million - $3.17 Million	10,000 Added 4.65%	225,000 $58.1 Million
Q2 2020 Aug 14, 2020	BUY	$123.9 - $195.41 $24,780 - $39,082	200 Added 0.09%	215,000 $40.5 Million
Q4 2018 Feb 14, 2019	SELL	$107.01 - $175.15 $21,402 - $35,030	-200 Reduced 0.09%	214,800 $30.1 Million
Q2 2018 Aug 14, 2018	SELL	$152.5 - $216.77 $953,125 - $1.35 Million	-6,250 Reduced 2.82%	215,000 $33.1 Million
Q1 2018 May 15, 2018	SELL	$97.41 - $177.22 $4.36 Million - $7.93 Million	-44,750 Reduced 16.82%	221,250 $37.2 Million
Q4 2017 Feb 14, 2018	SELL	$79.6 - $114.73 $1.11 Million - $1.61 Million	-14,000 Reduced 5.0%	266,000 $26 Million
Q3 2017 Nov 14, 2017	BUY	$66.19 - $103.46 $18.5 Million - $29 Million	280,000	280,000 $29 Million

250

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.8B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Rock Springs Capital Management LP with notifications on news.